Rationale: New pulmonary rehabilitation models can improve access to this effective but underused treatment for people with chronic respiratory disease; however, cost-effectiveness has not been det…
Rationale: Inhaled corticosteroids (ICSs) are the cornerstone of asthma treatment and significantly improve morbidity and mortality. Adverse effects of oral corticosteroids are well documented, but…
Despite living far away from Canada, Maryland residents experienced more cardiopulmonary disease health concerns in June 2023 believed to be due to Canadian wildfire pollution,…
Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to…
In this column, KFF President and CEO Drew Altman explores the state of consumer protections in health care and explains why, even with consumer frustration…
Rationale: The progression of lung changes in cystic fibrosis (CF) from infancy through adolescence remains poorly understood as a result of limited longitudinal imaging data.…
Neurovalens, maker of the FDA-cleared Modius Sleep device for chronic insomnia, will join the National Sleep Foundation (NSF) at CES 2025.
It still remains a vexatious conundrum to address the why, how, and when to require young children with cystic fibrosis (CF) to undergo pulmonary imaging,…
Rationale: Although many studies have examined gene expression in lung tissue, the gene regulatory processes underlying emphysema are still not well understood. Finding efficient nonimaging…
This issue brief describes trends in health coverage in 2022, examines the characteristics of the nonelderly uninsured population, and summarizes the access and financial implications…
Chronic obstructive pulmonary disease (COPD) is a devastating disease with escalating prevalence worldwide (1). Although the pathophysiology and diagnostic definition rely on irreversible airflow limitation,…
